ライフサイエンスコーパス: pseudopeptide

1 hes to the target phosphinic acid containing pseudopeptide.

2 ted derivatives of both diastereomers of the pseudopeptide.

3 lass of phosphorus compounds, thiophosphinyl pseudopeptides.

4 developed in order to access polyfunctional pseudopeptides.

5 ide replacements in some biologically active pseudopeptides.

6 the synthesis of N-(hydroxy)amide-containing pseudopeptides.

7 er, because the conformationally constrained pseudopeptide 10 was significantly more potent than its

8 This pseudopeptide, [6-Pha-Ala0]Lom-MT-II, was found to have

9 The pseudopeptides 7-9 were found to be competitive inhibito

10 this goal, the conformationally constrained pseudopeptides 8 and 10 and their corresponding flexible

11 Pseudopeptides 8 and 9 were found to be weak competitive

12 olution by the two cyclopropane rings in the pseudopeptides 9-12 appears to correspond closely to the

13 Pseudopeptides 9-12 were found to be competitive inhibit

14 Antimicrobial cyclic pseudopeptides (ACPPs) are based on the properties of an

15 resin afforded 3,4-ketomethylene-stabilized pseudopeptide analogs of thymopentin.

16 JMV594 ([d-Phe(6),Stat(13)]Bn(6-14)), and a pseudopeptide analogue, JMV641 (d-Phe-Gln-Trp-Ala-Val-Gl

17 straints to reduce the flexibility of linear pseudopeptides and to help enforce the biologically acti

18 The pseudopeptide antibiotic andrimid is a nanomolar inhibit

19 However, en route to the target pseudopeptide, Arbuzov reaction of RP(OTMS)(2) with a cy

20 The assembly of beta-peptides, peptoids and pseudopeptides are also evaluated in this critical revie

21 Conformational differences of the pseudopeptide backbones and the presence of disordered w

22 ich the cysteine is linked through a reduced pseudopeptide bond to 4-amino-3'-carboxybiphenyl.

23 glycine esters were converted to the desired pseudopeptides by Michael addition to alpha-methyleneglu

24 conformationally constrained, diastereomeric pseudopeptides CAbuPsi[COcpCO]FM 7-9, the flexible analo

25 Structural studies of the pseudopeptides carried out by NMR and circular dichroism

26 are mimics with normal bases connected to a pseudopeptide chain that obey Watson-Crick rules to form

27 yamide or N-(hydroxy)thioamide linkages into pseudopeptide chains without racemization.

28 g of the cytosol-open model could identify a pseudopeptide competitive inhibitor showing >100-fold hi

29 De novo cyclic pseudopeptides composed of alpha-amino and aza-beta(3)-a

30 conformational analysis of such beta-lactam pseudopeptides conducted in CDCl(3) and DMSO-d(6) soluti

31 ong-range chiral effects on the alpha-lactam pseudopeptide conformers were also found when two (i) an

32 A series of pseudopeptides containing alkyl-, cycloalkyl-, aryl-, an

33 The first three-dimensional structures of pseudopeptides containing aza-beta(3)-amino acids in aqu

34 N-Blocked pseudopeptides containing Val(k)Phe, Ala(k)Phe, and Val(

35 The bombesin-based pseudopeptide DOTA-4-amino-1-carboxymethylpiperidine-d-P

36 The pseudopeptides experience a significant degree of flexib

37 ure of the substitution, this can render the pseudopeptides inactive or lead to a drastic enhancement

38 o induce conformational constraints in known pseudopeptide inhibitors of a number of important enzyme

39 or PfMetAP-II as well as to screen two novel pseudopeptide inhibitors of MetAPs.

40 This pseudopeptide is designed from our previously reported R

41 These findings show that amphiphilic pseudopeptide mimics of insect neuropeptides will penetr

42 Novel enantiopure pseudopeptide models containing a central -(beta-lactam)

43 Ester prodrugs of the phosphinate pseudopeptide N-[(4-deoxy-4-amino-10-methyl)pteroyl]glut

44 Our results show that the multivalent pseudopeptide N6L inhibited Matrigel invasion of MDA-MB-

45 his study analyzed the role of ketomethylene pseudopeptides of thymopentin as potential agents for th

46 merization of a alpha5beta1 integrin-binding pseudopeptide on the triazacyclononane-triphosphinate (T

47 ra and aid in the design of peptidomimetics, pseudopeptides or small molecules capable of disrupting

48 N-Prolinylanthranilamide-based pseudopeptide organocatalyst 14 was shown to promote ena

49 A synthetic pseudopeptide, [Phe(1)iota(CH(2)-NH)Gly(2)]-nociceptin(1

50 Although the pseudopeptide prodrugs were ineffective, prodrugs of met

51 ltransferase are described which are reduced pseudopeptides related to the C-terminal tetrapeptide of

52 eatment with fluoromethyl ketone-derivatized pseudopeptides rescued mice from lethal infection.

53 To achieve cure of infection, this pseudopeptide scaffold was incorporated in a less toxic

54 The optimal pseudopeptide scaffold was phenylalanine-homophenylalani

55 the synthesis of a library of thioacetylated pseudopeptides that were screened against human sirtuins

56 1 and ERAP2 to design and develop phosphinic pseudopeptide transition state analogs that can inhibit

57 This pseudopeptide was more stable in serum than 26RFa((20-26

58 A tris(carbobenzyloxy)arginyl(k)norleucine pseudopeptide was synthesized and coupled to Asp-Val-Phe

59 All of these pseudopeptides were less potent than the tetrapeptide pa

60 Studies of the SAR of these alkylated pseudopeptides with concomitant modification of the side